These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22487791)

  • 1. The management of drooling in adults with neurological conditions.
    Squires N; Wills A; Rowson J
    Curr Opin Otolaryngol Head Neck Surg; 2012 Jun; 20(3):171-6. PubMed ID: 22487791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drooling in neuropediatric patients].
    Steffen A; Ortfeld S; Schönweiler R
    Klin Padiatr; 2011 Jan; 223(1):5-9. PubMed ID: 21271513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The current approach to hyper-sialorrhea].
    Defossez W
    Rev Belge Med Dent (1984); 2006; 61(3):173-9. PubMed ID: 17408138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialorrhea: a management challenge.
    Hockstein NG; Samadi DS; Gendron K; Handler SD
    Am Fam Physician; 2004 Jun; 69(11):2628-34. PubMed ID: 15202698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
    Wilken B; Aslami B; Backes H
    Neuropediatrics; 2008 Aug; 39(4):200-4. PubMed ID: 19165707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drooling of saliva: a review of the etiology and management options.
    Meningaud JP; Pitak-Arnnop P; Chikhani L; Bertrand JC
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jan; 101(1):48-57. PubMed ID: 16360607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.
    Reddihough D; Erasmus CE; Johnson H; McKellar GM; Jongerius PH;
    Eur J Neurol; 2010 Aug; 17 Suppl 2():109-21. PubMed ID: 20633182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drooling.
    Scully C; Limeres J; Gleeson M; Tomás I; Diz P
    J Oral Pathol Med; 2009 Apr; 38(4):321-7. PubMed ID: 19236564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypersalivation - inauguration of the S2k Guideline (AWMF) in short form].
    Steffen A; Beutner D; Hakim S; Jost W; Kahl KG; Laskawi R; Lencer R; Mall V; Mehrhoff FW; Meyners T; Schönweiler R; Schröder S; Schröter-Morasch H; Schuster M; Steinlechner S; Winterhoff J; Zenk J; Guntinas-Lichius O;
    Laryngorhinootologie; 2013 Aug; 92(8):515-22. PubMed ID: 23900923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing children with sialorrhoea (drooling): Experience from the first 301 children in our saliva control clinic.
    Montgomery J; McCusker S; Lang K; Grosse S; Mace A; Lumley R; Kubba H
    Int J Pediatr Otorhinolaryngol; 2016 Jun; 85():33-9. PubMed ID: 27240493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evidence-based approach to the child who drools saliva.
    Little SA; Kubba H; Hussain SS
    Clin Otolaryngol; 2009 Jun; 34(3):236-9. PubMed ID: 19531173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study.
    Wu KP; Ke JY; Chen CY; Chen CL; Chou MY; Pei YC
    J Child Neurol; 2011 Jul; 26(7):838-43. PubMed ID: 21551374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drooling in the developmentally disabled: management practices and recommendations. Consortium on Drooling.
    Blasco PA; Allaire JH
    Dev Med Child Neurol; 1992 Oct; 34(10):849-62. PubMed ID: 1397726
    [No Abstract]   [Full Text] [Related]  

  • 14. Botulinum toxin effect on salivary flow rate in children with cerebral palsy.
    Jongerius PH; Rotteveel JJ; van Limbeek J; Gabreëls FJ; van Hulst K; van den Hoogen FJ
    Neurology; 2004 Oct; 63(8):1371-5. PubMed ID: 15505151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drooling therapy in children with neurological disorders].
    Táboas-Pereira MA; Paredes-Mercado C; Alonso-Curcó X; Badosa-Pagès J; Muchart J; Póo P
    Rev Neurol; 2015 Jul; 61(2):66-70. PubMed ID: 26156441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinum toxin A for the treatment of sialorrhea in familial dysautonomia.
    Daniel SJ; Cardona I
    Int J Pediatr Otorhinolaryngol; 2014 May; 78(5):879-81. PubMed ID: 24725647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
    Jongerius PH; van den Hoogen FJ; van Limbeek J; Gabreëls FJ; van Hulst K; Rotteveel JJ
    Pediatrics; 2004 Sep; 114(3):620-7. PubMed ID: 15342830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care.
    Van der Burg JJ; Jongerius PH; Van Hulst K; Van Limbeek J; Rotteveel JJ
    Dev Med Child Neurol; 2006 Feb; 48(2):103-7. PubMed ID: 16417664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands.
    Turk-Gonzales M; Odderson IR
    Neurorehabil Neural Repair; 2005 Mar; 19(1):58-61. PubMed ID: 15673844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.